Sangamo Secures $50M Upfront in Neurodegenerative Pact with Roche’s Genentech

Partnership Details::
Sangamo has secured a $50 million upfront payment in a neurodegenerative disease-focused licensing deal with Roche's Genentech.

Total Potential Value::
The deal includes up to $1.9 billion in milestone payments, bringing the total potential value to over $2 billion.

Significance::
This partnership is crucial for Sangamo, as it provides significant financial support and validates their research efforts in neurodegenerative diseases.

Recent Developments::
Despite previous partnerships with Biogen and Novartis ending, Sangamo has successfully attracted investment from Roche's Genentech.

Industry Impact::
This deal highlights the growing interest and investment in neurodegenerative disease research within the biotech industry.